Page 1,638«..1020..1,6371,6381,6391,640..1,6501,660..»

Can fast and furious exercise prevent diabetes? – Medical Xpress

Posted: March 1, 2017 at 11:40 pm

March 1, 2017 Patients with fatty liver disease may need a more intense dose of exercise. Credit: University of Queensland

Short bursts of high-intensity exercise could help people with non-alcoholic fatty liver disease reduce their risk of type 2 diabetes.

A trial led by University of Queensland School of Human Movement and Nutrition Sciences researcher Dr Shelley Keating will investigate if high intensity interval training (HIIT) can improve insulin sensitivity, fitness and other cardiovascular disease risk factors.

"Other than weight loss, there is no accepted therapy for improving non-alcoholic steatohepatitis (NASH) a type of fatty liver disease which is strongly linked to type 2 diabetes and cardiovascular disease," Dr Keating said.

"We have recently demonstrated that exercise therapy reduces liver fat in adults with obesity, but patients with NASH may need a more intense 'dose' of exercise.

"We hope to establish that high-intensity exercise is a safe, feasible and effective therapy for improving insulin resistance and other cardio-metabolic risk factors.

"Given that up to one-third of Australians have non-alcoholic fatty liver disease, and the subsequent rate of progression to NASH is around 30 per cent, the impact on the community is significant."

Study participants will complete 12 weeks of HIIT supervised by an accredited exercise physiologist at UQ's St Lucia campus in Brisbane, followed by 12 weeks of HIIT at home.

"The sessions will involve short, intense bursts of exercise around four minutes on a treadmill or exercise bike at near maximum capacity - interspersed with more moderate exercise," Dr Keating said.

"Health measures including insulin sensitivity, body composition, vascular function, and fitness will be assessed before and after the supervised and home-based phases.

"It is very important that individuals can continue on with HIIT in the long-term so that the health benefits can be sustained," Dr Keating said.

People with biopsy-proven NASH, or their clinicians, should contact Dr Keating (see below) for details on how to take part in the trial.

Explore further: Diet and exercise can improve kidney function in patients with fatty liver disease

Non-alcoholic steatohepatitis (NASH) is a potentially serious liver condition characterized by excess fat in the liver associated with inflammation and scarring. NASH may progress to cirrhosis of the liver and liver cancer, ...

(Medical Xpress)High-intensity interval training (HIIT) is touted as the fastest way to get lean, but according to ground-breaking new research from the University of Sydney's Charles Perkins Centre, only endurance exercise ...

A University of Queensland researcher is trialling a 12-minute exercise plan that aims to fight type 2 diabetes in a flash.

Listening to music may make it easier for people to adopt short duration exercise regimens that could help them stay in shape, according to researchers at UBC's Okanagan campus.

Understanding how exercise affects language learning could help patients with brain conditions such as stroke, Alzheimer's and Parkinson's disease.

Time-poor people who do fewer repetitions during high-intensity interval training (HIIT) workouts may get better fitness benefits than those who complete more, according to a University of Stirling analysis.

Short bursts of high-intensity exercise could help people with non-alcoholic fatty liver disease reduce their risk of type 2 diabetes.

A diet designed to imitate the effects of fasting appears to reverse diabetes by reprogramming cells, a new USC-led study shows.

(Medical Xpress)A team of researchers with members from several institutions in Germany and one in the U.K. has discovered what might be a way to tell if a newborn child is likely to develop type 1 diabetes as they grow ...

People with diabetes are at high risk of developing heart disease. Despite knowing this, scientists have struggled to trace the specific biology behind that risk or find ways to intervene. Now, UNC School of Medicine researchers ...

A long-term study by Monash University researchers - the first of its kind - has found that gastric band surgery has significant benefits for moderately overweight people with type 2 diabetes. Previous studies have focused ...

Blood sugar triggers the secretion of insulin from cells in the pancreas, a process that is impaired in diabetes. A team of Yale researchers have identified a mechanism at the membranes of these pancreatic cells that controls ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Original post:
Can fast and furious exercise prevent diabetes? - Medical Xpress

Posted in Diabetes | Comments Off on Can fast and furious exercise prevent diabetes? – Medical Xpress

US Stem Cell, Inc. (OTCMKTS: USRM) Shares Spike Higher By 62% – Street Register

Posted: February 28, 2017 at 12:44 pm

Shares of U.S. Stem Cell, Inc. (OTCMKTS: USRM) are surging early in the session today. The stock price is up over 62% on heavy volume. According to OTC Markets, the stock over the last 30 days trades about 15.6M shares per day, however; more than 43.5M shares have traded thus far. The stock price is currently trading around $0.19.

U.S. Stem Cell, Inc. (OTCMKTS: USRM) is a biotech company dedicated to expanding regenerative medicine. Weve seen shares rise significantly in 2017. However, that doesnt come without its fair share of volatility. Over the last 52-weeks the stock has traded in a range between $0.0016 to $0.40.

Nonetheless, we have not seen any news in U.S. Stem Cell, Inc. (OTCMKTS: USRM) to justify the move today. Based on Fridays close, the company had a market cap of around $697K. In addition, has a one star quantitative valuation from Morningstar.

About U.S. Stem Cell, Inc.

Founded in 1999, U.S Stem Cell, Inc. is committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the bodys own healing potential, we may be able to reverse damaged tissue to normal function. U.S. Stem Cells discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. U.S Stem Cell is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.

Most Recent Headline:

CSO Kristin Comella Publishes Paper on the Implantation of Stromal Vascular Fraction in Patients with Degenerative Disc Disease

SUNRISE, FL / ACCESSWIRE / January 23, 2017 / US STEM CELL, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to announce our newest publication by our Chief Scientific Officer, Kristin Comella.

Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease was published in the January volume of the Journal of Translational Medicine. The study focused on the implantation of stromal vascular fraction (SVF) in patients suffering from degenerative disc disease. Patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered directly into the damaged discs. Patients were monitored for a period of 6 months post-treatment, noting considerable decreases in pain and increases in flexion. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/28086781.

Ms. Comellas previous paper, Effects of the intramyocardial implantation of stromal vascular fraction in patients with chronic ischemic cardiomyopathy, was released in the Journal of Translational Medicines June 2016 edition. Using the same procedure, chronic ischemic cardiomyopathy patients were evaluated after SVF injection and able to walk more than 80 additional meters 3 to 6 months after treatment. A copy of the paper can be accessed on pubmed: https://www.ncbi.nlm.nih.gov/pubmed/27255774.

At U.S. Stem Cell, Inc., we are committed to new technological advancements and therapies that give a renewed sense of hope to patients with degenerative diseases. SVF is the latest therapy in a long line of successful treatments we have pioneered. Ms. Comella plans to continue her work with SVF, which has consistently repeated its strong safety profile and success in treating patients.

Weve seen a tremendous amount of volatility in the biotech and medical space thus far this year. It will be interesting to see how politics play a role in stocks like USRM. If youd like to keep up with biotech stocks like USRM, make sure to sign up to our newsletter below. We make it quick and easy for our subscribers to stay on top of the markets. And yes, its free Which makes our membership affordable for everyone.

See the rest here:
US Stem Cell, Inc. (OTCMKTS: USRM) Shares Spike Higher By 62% - Street Register

Posted in Cell Medicine | Comments Off on US Stem Cell, Inc. (OTCMKTS: USRM) Shares Spike Higher By 62% – Street Register

Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM … – EconoTimes

Posted: February 28, 2017 at 12:44 pm

Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM) to Fund AlloJoin Allogeneic Stem Cell Therapy for Knee Osteoarthritis (KOA) in the U.S.

SHANGHAI, China and CUPERTINO, Calif., Feb. 27, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG)(CBMG or the Company), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that the governing Board of the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, has awarded the Company $2.29 million to support pre-clinical studies of AlloJoinTM, CBMGs Off-the-Shelf Allogeneic Human Adipose-derived Mesenchymal Stem Cells for the treatment of Knee Osteoarthritis in the United States.

While CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL) and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoinTM in Knee Osteoarthritis (KOA), this latest announcement represents CBMGs initial entrance into the United States for its off-the-shelf allogeneic stem cell candidate AlloJoinTM.

The $2.29 million was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. After the award, CIRM will be a more active partner with its recipients to further increase the likelihood of clinical success and help advance a pre-clinical applicants research along a funding pipeline towards clinical trials. CBMGs KOA pre-clinical program is considered late-stage, and therefore it meets CIRM 2.0s intent to accelerate support for clinical stage development for identified candidates of stem cell treatments that demonstrate scientific excellence.

"We are deeply appreciative to CIRM for their support and validation of the therapeutic potential of our KOA therapy, said Tony (Bizuo) Liu, Chief Executive Officer of CBMG. We thank Dr. C. Thomas Vangsness, Jr., in the Department of Orthopaedic Surgery at the Keck School of Medicine of the University of Southern California and Dr. Qing Liu-Michael at the Broad Center for Regenerative Medicine and Stem Cell Research at USC, who helped significantly with the grant application process. The CIRM grant is the first step in bringing our allogeneic human adipose-derived mesenchymal stem cell treatment for knee osteoarthritis (AlloJoinTM) to the U.S. market.

Our AlloJoinTM program has previously undergone extensive manufacturing development and pre-clinical studies and is undergoing a Phase I clinical trial in China. In order to demonstrate comparability with cell banks previously produced in China for our U.S. IND filing, we are addressing the pre-clinical answers required for the FDA. With the funds provided by CIRM, we will replicate and validate the manufacturing process and control system at the cGMP facility located at Childrens Hospital Los Angeles to support the filing of an IND with the FDA. The outcome of this grant will enable us to have qualified final cell products ready to use in a Phase I clinical trial with Dr. Vangsness as the Principal Investigator and the Keck School of Medicine of USC as a trial site. Dr. Vangsness is familiar with both stem cell biology and KOA, and has led the only randomized double-blind human clinical study to investigate expanded allogeneic mesenchymal stem cells to date. Our endeavor in the U.S. market will further strengthen our commercialization pipeline.

CBMG recently announced promising interim 3-month safety data from its Phase I clinical trial in China for AlloJoinTM, its off-the-shelf allogeneic stem cell therapy for KOA. The trial is on schedule to be completed by the third quarter of 2017.

About CIRM

At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and to act with a sense of urgency commensurate with that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies.

With $3 billion in funding and over 280 active stem cell programs in our portfolio, CIRM is the world's largest institution dedicated to helping people by bringing the future of medicine closer to reality.

For more information, please visit http://www.cirm.ca.gov.

About Knee Osteoarthritis

According to the Foundation for the National Institutes of Health, there are 27 million Americans with Osteoarthritis (OA), and symptomatic Knee Osteoarthritis (KOA) occurs in 13% of persons aged 60 and older. The International Journal of Rheumatic Diseases, 2011 reports that approximately 57 million people in China suffer from KOA. Currently no treatment exists that can effectively preserve knee joint cartilage or slow the progression of KOA. Current common drug-based methods of management, including anti-inflammatory medications (NSAIDs), only relieve symptoms and carry the risk of side effects. Patients with KOA suffer from compromised mobility, leading to sedentary lifestyles; doubling the risk of cardiovascular diseases, diabetes, and obesity; and increasing the risk of all causes of mortality, colon cancer, high blood pressure, osteoporosis, lipid disorders, depression and anxiety. According to the Epidemiology of Rheumatic Disease (Silman AJ, Hochberg MC. Oxford Univ. Press, 1993:257), 53% of patients with KOA will eventually become disabled.

About Cellular Biomedicine Group (CBMG)

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMGs scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit http://www.cellbiomedgroup.com.

Forward-looking Statements

This press release contains forward-looking statementsincluding descriptions of plans, strategies, trends, specific activities, investments and other non-historical factsas defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently uncertain, and actual results could differ materially from those anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy (including the devaluation of the RMB by China in August 2015), and other risks detailed in CBMGs reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," "continue" or similar terms or their negations. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

Go here to read the rest:
Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM ... - EconoTimes

Posted in Cell Medicine | Comments Off on Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine (CIRM … – EconoTimes

Gene therapy "seems extraordinary" at fighting blood cancer in study, experts say – CBS News

Posted: February 28, 2017 at 12:43 pm

In this May 2016 photo provided by Kite Pharma, cell therapy specialists at the companys manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight cancer. The experimental gene therapy, called CAR-T cell, turns a patients own blood cells into specialized cancer killers.

Kite Pharma via AP

An experimental gene therapy that turns a patients own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday. In all, 82 percent of patients had their cancer shrink at least by half at some point in the study. Its sponsor, California-based Kite Pharma, is racing Novartis AG to become the first to win approval of the treatment, called CAR-T cell therapy, in the U.S. It could become the nations first approved gene therapy. A hopeful sign: the number in complete remission at six months 36 percent is barely changed from partial results released after three months, suggesting this one-time treatment might give lasting benefits for those who do respond well.

Play Video

Genes are at the core of our identity, and they have been at the center of stunning advances in medical diagnosis, gene therapy and alteration. B...

This seems extraordinary ... extremely encouraging, said one independent expert, Dr. Roy Herbst, cancer medicines chief at the Yale Cancer Center. The worry has been how long Kites treatment would last and its side effects, which he said seem manageable in the study. Follow-up beyond six months is still needed to see if the benefit wanes, Herbst said, but added, this certainly is something I would want to have available. The therapy is not without risk. Three of the 101 patients in the study died of causes unrelated to worsening of their cancer, and two of those deaths were deemed due to the treatment. It was developed at the governments National Cancer Institute and then licensed to Kite. The Leukemia and Lymphoma Society helped sponsor the study. Results were released by the company and have not been published or reviewed by other experts. Full results will be presented at the American Association for Cancer Research conference in April. The company plans to seek approval from the U.S. Food and Drug Administration by the end of March and in Europe later this year. The treatment involves filtering a patients blood to remove key immune system soldiers called T-cells, altering them in the lab to contain a gene that targets cancer, and giving them back intravenously. Doctors call it a living drug permanently altered cells that multiply in the body into an army to fight the disease. Patients in the study had one of three types of non-Hodgkin lymphoma, a blood cancer, and had failed all other treatments. Median survival for such patients has been about six months. Kite study patients seem to be living longer, but median survival isnt yet known. With nearly nine months of follow-up, more than half are still alive. Six months after treatment, 41 percent still had a partial response (cancer shrunk at least in half) and 36 percent were in complete remission (no sign of disease).

These scans show a 62-year-old man with non-Hodgkin lymphoma, at left in December 2015, and three months after treatment with Kite Pharmas experimental CAR-T cell therapy at MD Anderson Cancer Center in Houston. The scans are from a presentation by Drs. Fred Locke and Sattva Neelapu, provided by the American Society for Blood and Marrow Transplantation and Kite.

ASBMT/Kite Pharma via AP

The numbers are fantastic, said Dr. Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study and has been a paid adviser to Kite. These are heavily treated patients who have no other options.

One of his patients, 43-year-old Dimas Padilla of Orlando, was driving when he got a call saying his cancer was worsening, chemotherapy was no longer working, and there was no match to enable a second try at a stem cell transplant. I actually needed to park ... I was thinking how am I going to tell this to my mother, my wife, my children, he said. But after CAR-T therapy last August, he saw his tumors shrink like ice cubes and is now in complete remission. They were able to save my life, Padilla said. Of the study participants, 13 percent developed a dangerous condition where the immune system overreacts in fighting the cancer, but that rate is lower than in some other tests of CAR-T therapy. The rate fell during the study as doctors got better at detecting and treating it sooner. Roughly a third of patients developed anemia or other blood-count-related problems, which Locke said were easily treated. And 28 percent had neurological problems such as sleepiness, confusion, tremor or difficulty speaking, but these typically lasted just a few days, Locke said. Its a safe treatment, certainly a lot safer than having progressive lymphoma, and comparable to combination chemotherapy in terms of side effects, said the cancer institutes Dr. Steven Rosenberg, who had no role in Kites study. The first lymphoma patient Rosenberg treated this way, a Florida man, is still in remission seven years later. There were no cases of swelling and fluid in the brain in this or any other study testing Kites treatment, company officials said. That contrasts with Juno Therapeutics, which has had a CAR-T study put on hold twice after five patient deaths due to this problem. Company officials would not say what the treatment might cost, but other types of immune system therapies have been very expensive. Its also being tested for some other types of blood cancer.

2017 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.

Read this article:
Gene therapy "seems extraordinary" at fighting blood cancer in study, experts say - CBS News

Posted in Cell Therapy | Comments Off on Gene therapy "seems extraordinary" at fighting blood cancer in study, experts say – CBS News

Stem cell therapy can help treat diabetic heart disease – The … – Economic Times

Posted: February 28, 2017 at 12:43 pm

KARAIKAL: Recent advancements in stem cells research have given hope for successfully treating diabetic heart disease (DHD), renowned New Zealand-based researcher in cardiovascular diseases Dr Rajesh Katare said today.

DHD affected the muscular tissues of the heart leading to complications and it had been demonstrated that resident stem cells of myocardium can be stimulated to repair and replace e degenerated cardiac myocytes resulting in a novel therapeutic effect and ultimately cardiac regeneration, he said.

Katare, Director of Cardiovascular Research Division in the University of Otago, New Zealand, was delivering the keynote address at the continuing medical education programme on "Role of Micro-RNAs and stem cells in cardiac regeneration in diabetic heart disease" at the Karaikal campus of premier health institute JIPMER.

Presenting clinical evidences, Katare said stem cell therapy certainly presented a new hope for successfully treating DHD.

Jawaharlal Institute of Post Graduate Medical Education (JIPMER) Director Dr Subash Chandra Parija pointed out that it was the first such programme on the role of stem cells in cardiac regeneration in the whole of the country.

He said as diabetes was highly prevalent in the country, providing treatment for DHD had become a big challenge. Patients suffering from the condition have to undergo lifelong treatment and medications. "In this backdrop, advancements in stem cell therapy assume significance," he said.

Read the original here:
Stem cell therapy can help treat diabetic heart disease - The ... - Economic Times

Posted in Cell Therapy | Comments Off on Stem cell therapy can help treat diabetic heart disease – The … – Economic Times

Anti-Diabetes Plan Progressing In Kansas Legislature – KCUR

Posted: February 28, 2017 at 12:43 pm

When the Kansas Senate comes back after this weeks midsession break, it may consider legislation to form a comprehensive state plan to fight diabetes.

House Bill 2219 would instruct the Kansas Department of Health and Environment to conduct an analysis of state costs from diabetes, identify best practices to prevent and control the condition, and develop a budget to implement those practices.

It also would require the agency to report on the plans progress every two years.

Just before the break the House voted 117-7 to pass the bill, which is one of the main legislative priorities for the American Diabetes Association. Four other states passed similar plans in 2016, according to the organization.

According to the American Diabetes Association, diabetes affects almost 13 percent of the adult population in Kansas and leads to about $2 billion in health care costs annually.

The associations numbers include an estimated 69,000 Kansans who have undiagnosed diabetes. Numbers from the federal Centers for Disease Control and Prevention that include only those with diagnosed diabetes ranked Kansas at 21st highest in the country, at 9.5 percent.

People with diabetes are unable to produce or properly use insulin, a hormone that turns food into energy. There are two main forms:Type 1 diabetes, previously known as juvenile diabetes, andType 2 diabetes, the most common kind. Common complications of diabetes include heart and blood vessel disease, kidney damage, blindness and nerve damage.

Larry Smith is president of the National Diabetes Volunteer Leadership Council, a Kentucky-based nonprofit that testified for the Kansas bill. He said Kentucky was the first state to enact a diabetes action plan and about one-third of states have them now.

It has opened the eyes of the Legislature and the government that there is a problem and its a big drain on their budget, said Smith, whose daughter has Type 1 diabetes.

Smith said the push to fight diabetes in Kentucky began with Gov. Ernie Fletcher, a Republican physician who led the state from 2003 to 2007.

He realized the cost that diabetes put on the state budget was substantial and held them back on a number of things they wanted to do in terms of education or infrastructure and so forth, Smith said.

A similar bill died in the Kansas House in 2015. But Rep. Susan Concannon, a Republican from Beloit who brought this years bill, said the current version was voted through in part due to testimony from Rep. Blaine Finch, a Republican from Ottawa, and from his teenage daughter who has diabetes.

It was a little more meaningful for us this year to have one of our colleagues make it more personal, Concannon said.

Andy Marso is a reporter for KCURs Kansas News Service, a collaboration of KCUR, Kansas Public Radio and KMUW covering health, education and politics in Kansas. You can reach him on Twitter@andymarso. Kansas News Service stories and photos may be republished at no cost with proper attribution and a link back to kcur.org.

Read the original here:
Anti-Diabetes Plan Progressing In Kansas Legislature - KCUR

Posted in Diabetes | Comments Off on Anti-Diabetes Plan Progressing In Kansas Legislature – KCUR

China Diabetes Market Report 2017: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics – Research and … – Yahoo Finance

Posted: February 28, 2017 at 12:43 pm

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics" report to their offering.

China currently has the highest number of diabetics in the world. The disease has presently reached epidemic proportions in the adult population. Around three decades ago, less than one percent of the Chinese adult population had diabetes. These levels, however, have increased to around 12 percent - making it the diabetes capital of the world.

The rise of diabetes in China can be attributed to a number of factors. Driven by a strong economic growth over the past few decades, the Chinese population has become richer, fatter and less mobile. Apart from urbanisation and sedentary lifestyles, Chinese people are also genetically more vulnerable to diabetes compared to Europeans and many other population groups. Other factors such as poor awareness of health issues, high consumption of white rice, poor healthcare infrastructure, etc. have also driven the prevalence of the disease.

China's diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine. Fuelled by a continuous increase in healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country. This is creating lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined.

The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the China diabetes market in any form.

Key Topics Covered:

1 Preface

2 Research Methodology

3 Executive Summary

4 Introduction

5 Diabetes Disease Overview

6 China Diabetes Epidemiology

7 China Diabetes Market

For more information about this report visit http://www.researchandmarkets.com/research/9h3kbw/china_diabetes

View source version on businesswire.com: http://www.businesswire.com/news/home/20170228006026/en/

Read the original post:
China Diabetes Market Report 2017: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics - Research and ... - Yahoo Finance

Posted in Diabetes | Comments Off on China Diabetes Market Report 2017: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics – Research and … – Yahoo Finance

Washington-Lee student working to raise $100000 for diabetes research – Inside NoVA

Posted: February 28, 2017 at 12:43 pm

Ever since he was diagnosed with Type 1 diabetes as a fifth-grader at Claremont Elementary School, Alex Simmons has been committed to raising funds for the Juvenile Diabetes Research Foundation (JDRF).

Now a Washington-Lee High School sophomore, he moves closer to his goal of raising $100,000 for diabetes research during a Feb. 25 event that drew more than 130 neighbors and friends to the Lyon Park Community Center.

The party, which included a silent auction, was hosted by five Arlington families who have supported Simmons since his diagnosis. The event raised more than $15,000, with all proceeds going directly to the JDRF, and boosted Alex Simmonss fund-raising totals so far to $75,500 in donations.

Ever since our son Alex was diagnosed with diabetes five years ago, the JDRF has been a big part of our lives, said Anita Simmons, a new member of the board of directors of the Juvenile Diabetes Research Foundation Greater Chesapeake and Potomac Chapter. They provide hope and guidance for so many families as we learn to cope with this diagnosis and protect our childrens health.

At the celebration, guests enjoyed a fully catered dinner by the Hard Times Caf, beverages from Dogfish Alehouse, a silent auction and the musical sounds of the Roger Taylor Quartet as they connected over a common cause.

Many Arlington businesses made donations, including local artist Sabrina Cabada, independent bookstore One More Page and SPARK Business Academy.

Previous fund-raisers have included local basketball tournaments, small parties with a purpose and a bingo night hosted by Simmons grandmother, Alease Brooks, a resident of Arlingtons The Carlin.

Bill Parsons, executive director of the Greater Chesapeake and Potomac Chapter, said the Feb. 25 event was one of the largest peer-to-peer fund-raising events his organization has seen in this area.

The commitment this family has made to bringing awareness to juvenile-diabetes issues and raising money for research has been incredible, he added. We all love the Simmons family Anita Simmons is a force of nature.

Complications of juvenile diabetes can be disabling and life-threatening. Each day, Alex Simmons who over the winter played on the varsity boys basketball team at Washington-Lee must monitor his blood sugar levels and give himself six to eight insulin shots, yet he remains focused on the positive.

I am not on this journey alone, and my close friends, family and relatives make this process much easier for me, he said. I encourage everyone who can to please donate money to the Juvenile Diabetes Research Foundation, not only for me, but for all of the children throughout the country who dont have it as easy as I do.

Alex Simmons is now a youth ambassador for the organization, and also leads a team that takes part in the annual OneWalk event on the National Mall.

Anita Simmons said their family is especially grateful to Rich Kelly and Cindy MacIntyre of the Hard Times Caf for providing all of the food for the fund-raising event, as well as for the help they extended to Alex and his family when he was first diagnosed with the disease. The Kellys daughter also has Type 1 diabetes, and they are strong supporters of Juvenile Diabetes Research Foundation.

For information on Alex Simmons fund-raising efforts, see the Web site at http://bit.ly/2mmGi5g.

Read more:
Washington-Lee student working to raise $100000 for diabetes research - Inside NoVA

Posted in Diabetes | Comments Off on Washington-Lee student working to raise $100000 for diabetes research – Inside NoVA

Should Dentists Screen Periodonitits Patients for Diabetes? – Endocrinology Advisor

Posted: February 28, 2017 at 12:43 pm

Should Dentists Screen Periodonitits Patients for Diabetes?
Endocrinology Advisor
In people who had never been diagnosed with diabetes, the researchers found that 47% of the group with severe periodontitis had prediabetes, and 18.1% had type 2 diabetes. In the mild-to-moderate group, 46% were found to have prediabetes and 9.9% ...

Go here to read the rest:
Should Dentists Screen Periodonitits Patients for Diabetes? - Endocrinology Advisor

Posted in Diabetes | Comments Off on Should Dentists Screen Periodonitits Patients for Diabetes? – Endocrinology Advisor

‘Small Town Throwdown’ for Zach Standen on March 11 – The Redding Pilot

Posted: February 27, 2017 at 4:42 pm

Bobby Paultauf and his band will play the throwdown.

Those in the Redding, Easton area are probably aware of what happened to Joel Barlow High School student Zach Standen in the summer of 2016. Zach was in a devastating auto accident that left him partially paralyzed.

He needs hope and support from as many people as possible. He needs countless medical procedures in order to gain movement to his legs again through stem cell treatment due to a tragic car accident that made him paralyzed.

To help support Standens recovery, local musicians Bobby Paltauf, of the Bobby Paltauf Band, and Grayson Hugh, of Grayson Hugh & the Moon Hawks, will play a benefit show on Saturday, March 11 at the Fairfield Theater Company.

The family has started a GoFundMe account where people are able to donate to this expensive treatment. Lets all get together and help him walk again, Paultaufs mother, Tiffany, wrote in a press release.

Bobby Paltauf is a senior at Joel Barlow High School, where Standen goes.

Lets all get together and support local live music, especially where it benefits the hope of Zach being able to walk again, his mother wrote.

For the concert benefitting Standen, more information can be found on The Bobby Paltauf Band page on Facebook, and tickets are available at http://www.fairfieldtheatre.org.

Zach Standen coached soccer Oct. 8 at Seaside Park in Bridgeport with, back row, left to right, Mark Roman, Alastair Bruce and Peter Syku.

Standen may be helped by stem cell medical treatments that can be administered in Panama.

The Standen family is in discussions and communication with the Cell Medicine Institute in that country and are pursuing this line of treatment for the young man, who is paralyzed.

We have done much research into stem cell therapy for spinal cord injuries here in the U.S. and Canada, and there just are no clinical trials or clinics that have the experience and track record like this one, the family said in a recent letter. Cell Medicine has been doing this specific treatment since 2006 and has a 60% to 70% success rate of some kind of improvements in most patients within a year.

Each procedure costs $37,200, which includes all medical procedures and ancillary needs. This is not covered by medical insurance.

The family is hoping everyone reading this could go to his GoFundMe page and donate $25, to help Zachs recovery.

To donate, visit: https://www.gofundme.com/stem-cell-therapy-for-zach-standen.

See the original post:
'Small Town Throwdown' for Zach Standen on March 11 - The Redding Pilot

Posted in Cell Medicine | Comments Off on ‘Small Town Throwdown’ for Zach Standen on March 11 – The Redding Pilot

Page 1,638«..1020..1,6371,6381,6391,640..1,6501,660..»